Evidence map›Paper›PMID 35893781›Full record

ArticlePharmaceutics2022

Lung Cancer Targeted Chemoradiotherapy via Dual-Stimuli Responsive Biodegradable Core-Shell Nanoparticles.

Roshni Iyer, Harish Ramachandramoorthy, Trinh Nguyen, Cancan Xu, Huikang Fu, Tanviben Kotadia, Benjamin Chen, Yi Hong, Debabrata Saha, Kytai Truong Nguyen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Core-Shell Nanoparticles for Pulmonary Drug Delivery.Pharmaceutical nanotechnology · 2025
    Review
  3. Review
  4. Review
  5. Drug Delivery Approaches to Improve Tendon Healing.Tissue engineering. Part B, Reviews · 2023
    Review
  6. Review
  7. May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Roshni IyerDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Harish RamachandramoorthyDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.ORCID 0000-0002-3431-365X
Trinh NguyenDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Cancan XuDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Huikang FuDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Tanviben KotadiaDepartment of Biology, University of Texas at Arlington, Arlington, TX 76019, USA.
Benjamin ChenDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Yi HongDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Debabrata SahaDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Kytai Truong NguyenDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.

Funding

Cancer Prevention and Research Institute of Texas RP210206National Science Foundation 1554835
6 · The paper itself

Abstract

Lung cancer is one of the major causes of cancer-related deaths worldwide, primarily because of the limitations of conventional clinical therapies such as chemotherapy and radiation therapy. Side effects associated with these treatments have made it essential for new modalities, such as tumor targeting nanoparticles that can provide cancer specific therapies. In this research, we have developed novel dual-stimuli nanoparticles (E-DSNPs), comprised of two parts; (1) Core: responsive to glutathione as stimuli and encapsulating Cisplatin (a chemo-drug), and (2) Shell: responsive to irradiation as stimuli and containing NU7441 (a radiation sensitizer). The targeting moieties on these nanoparticles are Ephrin transmembrane receptors A2 (EphA2) that are highly expressed on the surfaces of lung cancer cells. These nanoparticles were then evaluated for their enhanced targeting and therapeutic efficiency against lung cancer cell lines. E-DSNPs displayed very high uptake by lung cancer cells compared to healthy lung epithelial cells. These nanoparticles also demonstrated a triggered release of both drugs against respective stimuli and a subsequent reduction in in vitro cancer cell survival fraction compared to free drugs of equivalent concentration (survival fraction of about 0.019 and 0.19, respectively). Thus, these nanoparticles could potentially pave the path to targeted cancer therapy, while overcoming the side effects of conventional clinical therapies.

Indexed as

chemoradiotherapynanoparticlesstimuli-responsivetargeted drug delivery

Identifiers

PMID35893781
PMCPMC9332477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.